FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/05/2026
Back to search
Official data from USPTO
S-DUAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
S-DUAL
ST13
US500000079365471Class
1, 5, 42
Filing
79365471
Registration
7876915
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
03/06/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
01/31/2023
Registration date
08/05/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/05/2025
Last transaction
03/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
BLAZICH, JOAN MICHELE
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Samsung Biologics Co., Ltd.
Representatives
Brian P. Gregg McNees Wallace & Nurick
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Multiple fusion proteins in raw material form for scientific or medical research use; diagnostic reagents for scientific or research use; enzymes for scientific or research purposes; bispecific antibody being monoclonal antibodies for in vitro scientific or medical research use; cell culture reagents for scientific and research use; monoclonal antibodies for in vitro scientific purposes; microorganisms for scientific or laboratory purposesother than for medical and veterinary use; biological preparations for scientific or industrial laboratory purposes; fusion proteins in raw material form for scientific or medical research laboratory purposes; polymerase for nucleic acid for scientific or laboratory purposes; biochemical preparations for scientific purposes; double antibody reagents for scientific purposes; double antibody reagents for scientific purposes in biotechnological product development; biological preparations for use in biotechnologyother than for medical and veterinary use; biochemical catalysts; chemical reagents for use in genetic research for non-medical purposes
Class 5
Reagents for measurement of HBs antibody for medical purposes; crude medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for activating cellular function; colostral antibodies for veterinary purposes; chemico-pharmaceutical preparations for treating ocular diseases; chemical preparations for use in DNA analysis for medical purposes; bacterial preparations for medical and veterinary use; chemical preparations for medical or veterinary purposesfor bispecific or multispecific antibodies and derivatives thereofto treat cancersinflammatory diseasesautoimmune diseasesinfectious diseases and cardiovascular diseasesneurological disorder and for related diagnostic or therapeutic usefor use in related assays; biotechnological preparations being reagents for medical purposes; biological reagents for medical purposes; biochemical preparations for medical usefor bispecific or multispecific antibodies and derivatives thereofto treat cancersinflammatory diseasesautoimmune diseasesinfectious diseases and cardiovascular diseasesneurological disorder and for related diagnostic or therapeutic usefor use in related assays; reagents for medical use; reagent paper for medical purposes; bispecific colostral antibody for medical purposes; medical diagnostic test strips for use in the field of blood analysis; trace element preparations for human usedietary and nutritional supplements; clinical medical reagents; therapeutic drugs for treating cancer and drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; antigens being pharmaceutical preparations for stimulating immune responses; colostral antibodies for medical purposes
Class 42
Research relating to sciencescientific research; multiple nucleic acid scientific analysis; molecular scientific analysis; development of biotechnology; biochemical analysis; drug discovery services; new product design services; pharmaceutical research and development; clinical research in the field of medicine; services for assessing the efficiency of pharmaceuticalsproduct quality testing; fusion protein scientific analysis; computer programming services in the medical field; medical laboratories; computer project management services relating to imaging medical data; medicine research being medical research; analysis and evaluation of medical product developmentproduct quality testing; providing scientific information on the testinginspection and research of medical products; scientific laboratory services relating to the production of bispecific antibody; drug development of bispecific antibody; scientific research and development for double antibody reagent; evaluating of clinical trial progressconducting clinical trials for others; conducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
36 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/12/2026
FIMP
FINAL DISPOSITION PROCESSED
02/12/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/05/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/17/2025
PUBO
PUBLISHED FOR OPPOSITION
06/17/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/16/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
05/15/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/15/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
05/15/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/15/2025
DOCK
ASSIGNED TO EXAMINER
05/06/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/06/2025
DOCK
ASSIGNED TO EXAMINER
11/30/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/31/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/14/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/14/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/20/2024
NREV
NOTICE OF REVIVAL - E-MAILED
05/20/2024
PETG
PETITION TO REVIVE-GRANTED
05/20/2024
PROA
TEAS PETITION TO REVIVE RECEIVED
05/20/2024
MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
05/16/2024
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
05/16/2024
RFNP
REFUSAL PROCESSED BY IB
11/22/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/02/2023
RFRR
REFUSAL PROCESSED BY MPU
11/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/02/2023
CNRT
NON-FINAL ACTION WRITTEN
11/01/2023
DOCK
ASSIGNED TO EXAMINER
10/30/2023
MAFR
APPLICATION FILING RECEIPT MAILED
03/24/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/20/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/16/2023
Continuous trademark protection
Get notified about every new filing that threatens S-DUAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.